We have analysed the differences in headache treatment between 612 subjects admitted for the first visit (“naive”) (F/M: 2.41; mean age = 37. 31 + 14.09 years) and 620 subjects who returned to the Headache Centre of the University of Modena and Reggio Emilia for a control visit (F/M: 3.18; mean age = 44. 30 + 15.37 years). Most patients suffered from migraine. As acute treatment, on the first visit 49.35% of them was taking drugs prescribed by a doctor; 41.50% was taking OTCs; 9.15% was not taking any drug. On the control visit, 81.29% of patients was taking prescription drugs; 15.81% OTCs; 2.90% was not taking drugs (overall Chi-square = 139.229, p<0.001). Non-selective analgesics were the most used drugs. Triptans were used by 9.1% of “naive” patients and by 31.8 % of patients attending the control visit (Fisher’s Z = 7.655, p <0.001). Nimesulide was the most used drug. A prophylactic treatment was made by 16.83% of “naive” patients, and by 58.23 % of patients admitted for the control visit (Fisher’s Z = 12.135, p<0.001). Antidepressants were the class of drugs most used for prophylaxis. Amitriptyline was the drug for prophylaxis most frequently used by patients attending the control visit, while flunarizine was the most frequently used by “naive” patients. In conclusion, few patients take prescription drugs, triptans, or drugs for prophylaxis before being examined in a specialized Centre.
Pharmacoepidemiology of headache treatment before and after referral to a specialist centre / Ferrari, Anna; Cicero, Afg; Pasciullo, G; Sternieri, E; Bertolini, A.. - ELETTRONICO. - 0(2003), pp. 55-55.
|Data di pubblicazione:||2003|
|Titolo:||Pharmacoepidemiology of headache treatment before and after referral to a specialist centre|
|Autore/i:||Ferrari, Anna; Cicero, Afg; Pasciullo, G; Sternieri, E; Bertolini, A.|
|Data del convegno:||26 – 29 Giugno 2003|
|Luogo del convegno:||Trieste|
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris